Faron fingers low bioactivity as possible cause of phase 3 flop

Faron Pharma
Faron initially identified an “unusually low mortality rate” in the placebo arm as a possible cause of the failure. (Faron)

Faron Pharmaceuticals has zeroed in on low levels of interferon-beta bioactivity to explain why its phase 3 traumakine trial failed comprehensively. The biotech is now testing product batches to assess whether the formulation is to blame for the lackluster data.

Early biomarker analysis suggests the level of interferon-beta bioactivity in the phase 3 differed from that seen in a previous phase 1/2 trial. Traumakine is a recombinant form of interferon-beta-1a. Faron thinks interferon-beta-1a enhances CD37 expression, triggering events that curb the vascular leaking and inflammation that affect patients with acute respiratory distress syndrome (ARDS).

Lower-than-expected interferon-beta activity would undermine the first step in that process, leading to poor patient outcomes. Faron is now working to identify the cause of the activity level.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

The investigation is looking at product batches to see if a formulation issue is responsible. Other avenues of investigation include administration and deactivation. At this stage it is unclear whether Faron will establish a convincing explanation for the failure. Even if to does, Faron may still struggle to plot a course back from a blow that wiped 80% off its stock price.

Turku, Finland-based Faron proceeded confidently into a pivotal ARDS study in the back of data from a phase 1/2 trial that linked traumakine to positive outcomes. But the pivotal 300-patient study failed to replicate the results of the smaller, earlier trial. Traumakine was no better than placebo at keeping patients alive and off ventilators.

Faron initially identified an “unusually low mortality rate” in the placebo arm as the possible culprit. All-cause mortality at 28 days in the control cohort of the phase 3 was nine percentage points lower than in the earlier study.

That is at best a partial explanation for the failure, though, as the mortality in the treatment arm was far higher in the phase 3 than the earlier trial. The 28-day all-cause mortality rate in the traumakine arm of the phase 1/2 was 8%. In the phase 3 trial, the figure was 26.4%, higher than was reported in the control arm.

Suggested Articles

IRhythm’s ECG patch was able to improve atrial fibrillation diagnoses and lower numbers of ER visits by shifting patients to outpatient settings.

Cold Genesys is developing its lead asset as a single agent and in combination therapies and has taken it through phase 2 in bladder cancer.

Dermira has generated evidence that its treatment for moderate-to-severe atopic dermatitis can pose a challenge to Regeneron and Sanofi’s Dupixent.